[{"id":"b13e6021-21ee-414a-b797-f317ed8e7f72","acronym":"3082-CL-0101","url":"https://clinicaltrials.gov/study/NCT05382559","created_at":"2022-05-19T11:56:18.696Z","updated_at":"2025-02-25T16:46:04.383Z","phase":"Phase 1","brief_title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","source_id_and_acronym":"NCT05382559 - 3082-CL-0101","lead_sponsor":"Astellas Pharma Inc","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • setidegrasib (ASP3082)"],"overall_status":"Recruiting","enrollment":" Enrollment 541","initiation":"Initiation: 06/08/2022","start_date":" 06/08/2022","primary_txt":" Primary completion: 10/31/2026","primary_completion_date":" 10/31/2026","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2025-02-05"}]